Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer
Lung Cancer
About this trial
This is an interventional diagnostic trial for Lung Cancer focused on measuring stage I non-small cell lung cancer
Eligibility Criteria
Patients with clinical stage I lung cancer for whom surgical resection is planned are eligible. Histologic confirmation of lung cancer is not required prior to registration or surgical exploration. Preoperative mediatinoscopy is allowed but not required in those patients with indications for mediatinoscopy. It is preferred that that mediatinoscopy be done at a different setting (prior to registration), but the procedure may be done at the same setting as the lobectomy. No prior therapy for this diagnosis. No prior treatment with mediastinal radiation therapy. Age ≥ 18 years of age. ECOG performance status: 0-2.
Sites / Locations
- Beebe Medical Center
- CCOP - Christiana Care Health Services
- Evanston Northwestern Healthcare - Evanston Hospital
- Veterans Affairs Medical Center - Columbia (Truman Memorial)
- Cancer Institute of New Jersey at Cooper - Voorhees
- Roswell Park Cancer Institute
- Elmhurst Hospital Center
- Queens Cancer Center of Queens Hospital
- Mount Sinai Medical Center
- SUNY Upstate Medical University Hospital
- Veterans Affairs Medical Center - Asheville
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
Arms of the Study
Arm 1
Experimental
Sentinal node mapping